Synonym
AZD-7624; AZD 7624; AZD7624;
IUPAC/Chemical Name
N-cyclopropyl-3-fluoro-4-methyl-5-(3-((1-(2-(2-(methylamino)ethoxy)phenyl)cyclopropyl)amino)-2-oxopyrazin-1(2H)-yl)benzamide
InChi Key
NNKPHNTWNILINE-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H30FN5O3/c1-17-21(28)15-18(25(34)31-19-7-8-19)16-22(17)33-13-11-30-24(26(33)35)32-27(9-10-27)20-5-3-4-6-23(20)36-14-12-29-2/h3-6,11,13,15-16,19,29H,7-10,12,14H2,1-2H3,(H,30,32)(H,31,34)
SMILES Code
O=C(NC1CC1)C2=CC(N3C(C(NC4(C5=CC=CC=C5OCCNC)CC4)=NC=C3)=O)=C(C)C(F)=C2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
The p38 protein kinases, in particular p38α and p38β, regulate the production of multiple inflammatory mediators. Consequentially, considerable effort has been focused on trying to develop p38 inhibitors for the treatment of inflammatory diseases
Preparing Stock Solutions
The following data is based on the
product
molecular weight
491.57
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Higham A, Karur P, Jackson N, Cunoosamy DM, Jansson P, Singh D. Differential
anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD
pulmonary cells. Int J Chron Obstruct Pulmon Dis. 2018 Apr 19;13:1279-1288. doi:
10.2147/COPD.S159936. eCollection 2018. PubMed PMID: 29719383; PubMed Central
PMCID: PMC5914546.
2: Patel NR, Cunoosamy DM, Fagerås M, Taib Z, Asimus S, Hegelund-Myrbäck T,
Lundin S, Pardali K, Kurian N, Ersdal E, Kristensson C, Korsback K, Palmér R,
Brown MN, Greenaway S, Siew L, Clarke GW, Rennard SI, Make BJ, Wise RA, Jansson
P. The development of AZD7624 for prevention of exacerbations in COPD: a
randomized controlled trial. Int J Chron Obstruct Pulmon Dis. 2018 Mar
27;13:1009-1019. doi: 10.2147/COPD.S150576. eCollection 2018. PubMed PMID:
29628759; PubMed Central PMCID: PMC5877500.
3: Pehrson R, Hegelund-Myrbäck T, Cunoosamy D, Asimus S, Jansson P, Patel N,
Borde A, Lundin S. AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung
Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure. J Pharmacol Exp
Ther. 2018 Jun;365(3):567-572. doi: 10.1124/jpet.117.246132. Epub 2018 Mar 16.
PubMed PMID: 29549158.
4: Gross N. The COPD Pipeline XXXII. Chronic Obstr Pulm Dis. 2016 Jul
14;3(3):688-692. doi: 10.15326/jcopdf.3.3.2016.0150. PubMed PMID: 28848893;
PubMed Central PMCID: PMC5556764.
5: Widdifield CM, Nilsson Lill SO, Broo A, Lindkvist M, Pettersen A, Svensk
Ankarberg A, Aldred P, Schantz S, Emsley L. Does Z' equal 1 or 2? Enhanced powder
NMR crystallography verification of a disordered room temperature crystal
structure of a p38 inhibitor for chronic obstructive pulmonary disease. Phys Chem
Chem Phys. 2017 Jun 28;19(25):16650-16661. doi: 10.1039/c7cp02349a. PubMed PMID:
28621371.
